Online inquiry

IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5263MR)

This product GTTS-WQ5263MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ5263MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3442MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AV-299
GTTS-WQ1735MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ADC-1013
GTTS-WQ12341MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ3702MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ6614MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ2460MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 181
GTTS-WQ5213MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CAT-8015
GTTS-WQ115MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 11F8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW